Break-out session 2

New CVRM: near-term opportunities

Elisabeth Björk, Senior Vice President, late-stage R&D

John Houghton, Global Franchise Head, roxadustat, late-stage R&D

Joris Silon, Senior Vice President, Head of CVRM, BioPharmaceuticals Business Unit

25 March 2021

Interactive event for investors and analysts. This webinar is being recorded.
https://astrazeneca.zoom.us/webinar/register/WN__3rpTdMKRnCrhrf2_j5HYA
Forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failure to obtain, defend and enforce effective intellectual property (IP) protection and IP challenges by third parties; the impact of competitive pressures including expiry or loss of IP rights, and generic competition; the impact of price controls and reductions; the impact of economic, regulatory and political pressures; the impact of uncertainty and volatility in relation to the UK’s exit from the EU; the risk of failures or delays in the quality or execution of the Group’s commercial strategies; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group’s medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology, data protection or cybercrime; the risk of failure of critical processes; any expected gains from productivity initiatives are uncertain; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to adhere to applicable laws, rules and regulations; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; the risk of failure to adhere to increasingly stringent anti-bribery and anti-corruption legislation; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group’s financial position; and the impact that the COVID-19 global pandemic may have or continue to have on these risks, on the Group’s ability to continue to mitigate these risks, and on the Group’s operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.
Farxiga

Building a new standard of care in cardiorenal disease

**Farxiga**

Broad development programme beyond T2D

**DECLARE Phase III (T2D)**
Positive cardiorenal benefit

**DAPA-HF Phase III (HFrEF)**
26% risk reduction

**DAPA-CKD Phase III (CKD)**
Reduced the worsening of renal function or renal or CV death by 39%

---

1. Type-2 diabetes
2. Heart failure (NYHA class II-IV) with reduced ejection fraction in patients with and without T2D
3. Chronic kidney disease. In patients with and without T2D
4. Cardiovascular
5. Defined as a composite of a sustained ≥50% estimated glomerular filtration rate (eGFR) decline, onset of end-stage kidney disease and death from CV or renal cause. Compared to placebo (p<0.0001).
**Farxiga**

**New and upcoming milestones**

- **DAPA-CKD Phase III (CKD)**
  - Regulatory decision US (H1 2021)
  - EU, JP, CN (H2 2021)

- **DELIVER Phase III (HFpEF)**
  - Data readout H2 2021

- **NEW trials**
  - Phase III DAPA-MI²
    - Achieved FPCD³
  - Phase II (CKD) AZD9977 + Farxiga
    - H1 2021

- **zibotentan + Farxiga AZD9977 + Farxiga**
  - Data readout

**~$2 billion**

FY 2020 revenue

71%

Revenue ex. US

---

1. Heart failure with preserved ejection fraction  
2. Myocardial infarction  
3. First patient commenced dosing.

US Q2 2020

Total revenue at actual exchange rates.
Silent, progressive, high-mortality disease; significantly underdiagnosed

CKD affects c.840m adults worldwide

>2 billion

People at risk of developing CKD

12%

Diagnosed with Stage 3 CKD

+40%

Increase in dialysis, transplant or death

Approach

Revolutionise: early diagnosis of CKD

Establish: Farxiga as SoC from prevention to treatment

Transform: management of complications with Lokelma and roxadustat

**Lokelma**

Rapid and sustained potassium control for patients with hyperkalaemia

**HK** is common in patients with chronic conditions

- **44%** of patients with HK also had CKD
- **22%** of patients with HK also had HF
- **58%** of patients with HK were also, on RAASI therapy

**DIALIZE Phase IIIb trial**

- The first randomised, placebo-controlled trial of a K+ binder in the treatment of HD patients with HK

**High efficacy in patients with normokalaemia 75% of the time**

- **Odds ratio 68.8 (95% CI 10.9-2810.9) p<0.001**

**FY2020: Global $76m; US $57m**

- US market leadership helps expand market

---


2. Potassium binder.

3. Haemodialysis.
Roxadustat

Shifting the treatment paradigm for patients with anaemia from CKD

**Unique characteristics**
- Leverages the body’s natural response to hypoxia
- Consistent Hb control across all patients
- Reduction in RBC transfusion risk
- Effect is independent of underlying inflammation
- Reduces the potential need for IV iron
- Pooled analysis demonstrated CV safety
- Convenient oral administration

**Key data from ASN 2020**
- MACE, MACE+, and CV event rates were lowest at achieved Hb levels ≥10 g/dL, in DD and NDD CKD patients
- Reduced risk of hospitalisation for HF vs. ESA in DD patients; consistent and large reduction in transfusion vs. placebo in NDD patients
- Not associated with an increased risk of neoplasm

**China $30m; focus on hospital listings and patient access**

**Next milestone: US FDA Cardiovascular and Renal Drugs Advisory Committee**

---


Expanding Farxiga from T2D and HF to CKD

New CVRM: near-term opportunities

Phase II
- roxadustat<sup>1</sup>
  - HIF-PH<sup>2</sup> inhibitor
  - chemo induced anaemia

Phase III
- Farxiga DAPA-MI
  - SGLT2<sup>3</sup>
  - prevention of HF and CV death following a MI
- Farxiga DELIVER
  - SGLT2
  - HFpEF
- roxadustat<sup>1</sup>
  - HIF-PH inhibitor
  - anaemia MDS<sup>4</sup>

Regulatory review
- Farxiga DAPA-CKD
  - SGLT2
  - CKD

Upcoming milestones

H1 2021
- Farxiga - CKD: regulatory decision (US)

H2 2021
- Forxiga - CKD: regulatory decision (EU, JP, CN)
- Farxiga - HF (HFpEF): data readout
- roxadustat - anaemia in CKD: Advisory Committee, regulatory decision (US)

2022
- Farxiga - HF (HFpEF): regulatory submission
- roxadustat - MDS: data readout, regulatory submission

Status as of 25 March 2021.
Questions & Answers

To ask a question

*Webinar*
Click ‘Raise Hand’ (preferred):

* [Image]

or type your question into the Q&A box (alternative)

*Phone*
*6 - Toggle mute/unmute
*9 - Raise hand
Appendix
## Publications

### Farxiga

<table>
<thead>
<tr>
<th>Trial</th>
<th>Journal</th>
<th>Title</th>
<th>Author</th>
<th>Citation</th>
</tr>
</thead>
</table>

### Lokelma

| Study 4, DIALIZE | *Journal of the American Society of Nephrology* | A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia | Fishbane, S et al.         | *JASN* September 2019, 30 (9) 1723-1733 |
| Study 3         | *Clinical Journal of the American Society of Nephrology* | Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia     | Spinowitz, B.S et al.      | *CJASN* June 2019, 14 (6) 798-809 |
## Roxadustat

<table>
<thead>
<tr>
<th>Trial</th>
<th>Journal</th>
<th>Title</th>
<th>Author</th>
<th>Citation</th>
</tr>
</thead>
<tbody>
<tr>
<td>OLYMPUS</td>
<td><em>Journal of the American Society of Nephrology</em></td>
<td><strong>Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study</strong></td>
<td>Fishbane, S et al.</td>
<td><em>JASN</em> March 2021, 32 (3) 737-755</td>
</tr>
<tr>
<td>HIMALAYAS</td>
<td><em>Nephrology Dialysis Transplantation</em></td>
<td><strong>Roxadustat for anemia in patients with end-stage renal disease incident to dialysis</strong></td>
<td>Provenzano, R et al.</td>
<td><em>Nephrology Dialysis Transplantation</em>, gfab051</td>
</tr>
</tbody>
</table>
Use of AstraZeneca conference call, webcast and presentation slides

The AstraZeneca webcast, conference call and presentation slides (together the ‘AstraZeneca materials’) are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make available to the public, sell or otherwise reuse or commercialise the AstraZeneca materials in any way. You may not edit, alter, adapt or add to the AstraZeneca materials in any way, nor combine the AstraZeneca materials with any other material. You may not download or use the AstraZeneca materials for the purpose of promoting, advertising, endorsing or implying any connection between you (or any third party) and us, our agents or employees, or any contributors to the AstraZeneca materials. You may not use the AstraZeneca materials in any way that could bring our name or that of any Affiliate into disrepute or otherwise cause any loss or damage to us or any Affiliate. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA. Telephone +44 20 3749 5000, www.astrazeneca.com